A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein-Reference-Cited by-同舟云学术

A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein

Published:2016-04-15 Issue:4 Volume:139 Page:916-927
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Amoury Manal¹,Mladenov Radoslav¹,Nachreiner Thomas¹,Pham Anh-Tuan¹,Hristodorov Dmitrij¹,Di Fiore Stefano²,Helfrich Wijnand³,Pardo Alessa¹,Fey Georg⁴,Schwenkert Michael⁵,Thepen Theophilus²,Kiessling Fabian⁶,Hussain Ahmad F.⁷,Fischer Rainer²,Kolberg Katharina¹²,Barth Stefan⁸

Affiliation:

1. Department of Experimental Medicine and Immunotherapy; Institute for Applied Medical Engineering, University Hospital RWTH Aachen; Germany

2. Department of Pharmaceutical Product Development; Fraunhofer Institute for Molecular Biology and Applied Ecology; Aachen Germany

3. Department of Surgery, Laboratory for Translational Surgical Oncology; University of Groningen, University Medical Center Groningen; The Netherlands

4. Department of Biology; Friedrich Alexander University Erlangen-Nuremberg; Germany

5. Bio-Rad AbD Serotec GmbH; Puchheim Germany

6. Institute for Experimental Molecular Imaging, University Hospital RWTH Aachen; Germany

7. Department of Gynecology and Obstetrics; University Hospital RWTH Aachen; Germany

8. South African Research Chair in Cancer Biotechnology, Institute of Infectious Disease and Molecular Medicine (IDM), Department of Integrative Biomedical Sciences, Faculty of Health Sciences; University of Cape Town; Observatory South Africa

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ijc.30119/fullpdf

Reference50 articles.

1. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial;Gianni;Lancet Oncol,2011

2. 2013 http://meetinglibrary.asco.org/content/237-132

3. Endocrine therapy of breast cancer;Lumachi;Curr Med Chem,2011

4. Understanding the biology of triple-negative breast cancer;Criscitiello;Ann Oncol,2012

5. Basal breast cancer: a complex and deadly molecular subtype;Bertucci;Curr Mol Med,2012

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy;Proceedings of the Japan Academy, Series B;2024-05-10

2. Chondroitin Sulfate Proteoglycan 4 Provides New Treatment Approach to Preventing Peritoneal Dissemination in Ovarian Cancer;International Journal of Molecular Sciences;2024-01-28

3. CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate;Journal of Cancer Research and Clinical Oncology;2023-07-11

4. Chondroitin sulfate proteoglycan 4 provides new treatment approach to prevent peritoneal dissemination in ovarian cancer;2023-03-16

5. CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil;Frontiers in Immunology;2022-11-22